With the exception of Thermo Fisher Scientific, which released three new instruments, vendors focused mainly on expanded applications of existing platforms.
The deal gives BD global distribution rights for several Bruker MALDI Biotyper products, expanding a 2010 agreement key to both firms' microbiology businesses.
The company reported total revenues of $384.9 million, up from $375.4 million for the first quarter of 2016 and above analysts' consensus estimate of $372.7 million.
Presented this week at the ECCMID annual meeting, the method uses mass spec to detect alterations to bacteria lipopolysaccharides that confer resistance.
A report from Leerink predicted Thermo Fisher Scientific could launch such a system within the next year, potentially opening up the clinical mass spec market.
Bruker said it plans to use InVivo assets to explore antibody enrichment methods that could eliminate the need for culturing prior to MALDI-based microbial ID.
